Immunocore posts $864M year-end cash estimate

Immunocore Holdings plc reported a preliminary estimate of its cash, cash equivalents and marketable securities of about $864 million as of December 31, 2025.

Rhea-AI Filing Summary

Immunocore Holdings plc reported a preliminary estimate of its cash, cash equivalents and marketable securities of about $864 million as of December 31, 2025. This figure is based on internal estimates, is unaudited and may change once full year-end financial statements are completed, and any adjustments identified by the company or its independent auditors could be material.

The company also outlined its strategic priorities for 2026 in a press release and updated its corporate presentation with business and strategy updates, including materials to be used at the 44th Annual J.P. Morgan Healthcare Conference. In addition, Immunocore published an updated pipeline chart for KIMMRAK (tebentafusp) and its development-stage therapeutic candidates. These materials are provided as exhibits and, where noted, are furnished rather than filed under securities law.

Insights

Biotech equity analyst

Immunocore highlights a sizable year-end cash estimate and refreshes its 2026 strategy and pipeline messaging.

Immunocore preliminarily pegs its cash, cash equivalents and marketable securities at about $864 million as of December 31, 2025. For a clinical- and commercial-stage biotech, this level of liquidity can be important for funding ongoing trials, commercialization efforts and pipeline expansion, although this excerpt does not quantify spending needs or cash burn.

The company stresses that this cash figure is unaudited and may change once year-end financial statements are finalized, with the possibility of material adjustments. That caveat means investors will need the full annual report to understand the final balance sheet and operating results.

Alongside the financial estimate, Immunocore released 2026 strategic priorities, an updated corporate presentation and an updated pipeline chart for KIMMRAK (tebentafusp) and other candidates. These materials, including the presentation for the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, frame how management is positioning its programs, but the specific strategic and clinical details reside in the attached exhibits.

8-K Event Classification

4 items: 2.02, 7.01, 8.01, 9.01

4 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What preliminary cash balance did Immunocore (IMCR) disclose as of December 31, 2025?

Immunocore preliminarily estimated that its cash, cash equivalents and marketable securities totaled approximately $864 million as of December 31, 2025.

Is Immunocore’s $864 million year-end 2025 cash estimate audited?

No. The company states the $864 million cash, cash equivalents and marketable securities figure is preliminary, unaudited and subject to change once audited financial statements are completed.

What strategic updates did Immunocore (IMCR) provide in this 8-K?

Immunocore issued a press release outlining its strategic priorities for 2026 and updated its corporate presentation with business and strategic updates, both attached as Exhibits 99.1 and 99.2.

What is included in Immunocore’s updated pipeline materials for KIMMRAK (tebentafusp)?

The company filed an updated pipeline chart for KIMMRAK (tebentafusp) and its therapeutic candidates in development as Exhibit 99.3, providing an overview of its pipeline stages.

How will Immunocore use its updated corporate presentation with investors and analysts?

Immunocore plans to use an abbreviated version of the updated corporate presentation in meetings with analysts, investors and others, including its management presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 8:15 a.m. PT.

Are Immunocore’s press release and presentation considered filed or furnished information?

The information in Item 7.01, including Exhibits 99.1 and 99.2, is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act.

Where can investors access Immunocore’s JPM Healthcare Conference presentation and webcast?

The corporate presentation and a webcast of Immunocore’s presentation at the 44th Annual J.P. Morgan Healthcare Conference will be available in the “Investors” section of www.immunocore.com.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/09/2026 - 07:11 AM Learn about SEC filing dates

false000167192700-000000000016719272026-01-092026-01-090001671927imcr:AmericanDepositarySharesEachRepresentingOneOrdinaryShareNominalValue0002PerShareMember2026-01-092026-01-090001671927imcr:OrdinaryShareNominalValue0002PerShareMember2026-01-092026-01-09false000167192700-0000000GBAmerican Depositary Shares, each representing one ordinary share, nominal value 0.002 per shareOrdinary share, nominal value 0.002 per share*NASDAQNASDAQ00016719272026-01-092026-01-090001671927imcr:AmericanDepositarySharesEachRepresentingOneOrdinaryShareNominalValue0002PerShareMember2026-01-092026-01-090001671927imcr:OrdinaryShareNominalValue0002PerShareMember2026-01-092026-01-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2026

Immunocore Holdings plc

(Exact name of registrant as specified in its Charter)

England and Wales	001-39992	Not Applicable
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

92 Park Drive, Milton Park Abingdon, Oxfordshire, United Kingdom		OX14 4RY
(Address of principal executive offices)		(Zip Code)

+44 1235 438600

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
American Depositary Shares, each representing one ordinary share, nominal value £0.002 per share	IMCR	The Nasdaq Stock Market LLC
Ordinary share, nominal value £0.002 per share*	*	The Nasdaq Stock Market LLC

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On January 9, 2026, Immunocore Holdings plc (the “Company”) announced a preliminary estimate of the amount of its cash, cash equivalents and marketable securities at December 31, 2025. The Company preliminarily estimates that its cash, cash equivalents and marketable securities as of December 31, 2025 were approximately $864 million.

The information in this Item 2.02 is preliminary, has not been audited and is subject to change pending completion of the Company’s audited financial statements for the year ended December 31, 2025. It is possible that the Company or its independent registered public accounting firm may identify items that require the Company to make adjustments to the amounts included in this Item 2.02, and such changes could be material. Additional information and disclosures would also be required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2025.

Item 7.01. Regulation FD Disclosure.

On January 9, 2026, the Company issued a press release announcing its strategic priorities for 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Also on January 9, 2026, the Company updated its corporate presentation to reflect certain business and strategic updates. The Company intends to use an abbreviated version of the presentation in meetings with analysts, investors and others from time to time, including its presentation by management at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 8:15 a.m. PT. A copy of the presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein. The corporate presentation and a webcast of the Company’s presentation at the 44th Annual J.P. Morgan Healthcare Conference will also be available in the “Investors” section of the Company’s website at www.immunocore.com. The Company’s website and any information contained on the Company’s website are not incorporated by reference into this Current Report on Form 8-K.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

On January 9, 2026, the Company published an updated pipeline chart of KIMMRAK (tebentafusp) and its therapeutic candidates in development, which is filed as Exhibit 99.3 to this Current Report on Form 8-K and incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

Exhibit No.	Description
99.1	Press Release dated January 9, 2026.
99.2	Corporate Presentation, dated January 2026.
99.3	Pipeline Chart.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMMUNOCORE HOLDINGS PLC
Dated: January 9, 2026	By:	/s/ Bahija Jallal, Ph.D.
	Name:	Bahija Jallal, Ph.D.
	Title:	Chief Executive Officer